Literature DB >> 35473670

Correction to: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.

Ahmed B Bayoumy1,2,3,4, Elsa L S A van Liere5,6,7,8, Melek Simsek9, Ben Warner6, Aathavan Loganayagam7, Jeremy D Sanderson6, Simon Anderson6, Jonathan Nolan8, Nanne K de Boer9, Chris J J Mulder5, Azhar Ansari8.   

Abstract

Entities:  

Year:  2022        PMID: 35473670      PMCID: PMC9044855          DOI: 10.1186/s12876-021-01992-2

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


× No keyword cloud information.

Correction to: BMC Gastroenterology (2020) 20:296 10.1186/s12876-020-01441-6

After publication of this article [1], the authors reported three adjustments: Competing interests: the travel grants were paid by HLW Pharma instead of TEVA Pharma. TGN-units all over the manuscript have to be adjusted from pmol/8 × 105 RBC to pmol/8 × 108 RBC. Some minor textual adjustments. The original article [1] has been updated.
  1 in total

1.  Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.

Authors:  Ahmed B Bayoumy; Elsa L S A van Liere; Melek Simsek; Ben Warner; Aathavan Loganayagam; Jeremy D Sanderson; Simon Anderson; Jonathan Nolan; Nanne K de Boer; Chris J J Mulder; Azhar Ansari
Journal:  BMC Gastroenterol       Date:  2020-09-11       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.